N/A
Manufactured by Dalim Tissen
3,219 FDA adverse event reports analyzed
Last updated: 2026-04-15
ADENOSINE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Dalim Tissen. The most commonly reported adverse reactions for ADENOSINE include DRUG INEFFECTIVE, OFF LABEL USE, SUPRAVENTRICULAR TACHYCARDIA, HYPOTENSION, CARDIAC ARREST. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ADENOSINE.
Out of 1,547 classified reports for ADENOSINE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 3,219 FDA FAERS reports that mention ADENOSINE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, OFF LABEL USE, SUPRAVENTRICULAR TACHYCARDIA, HYPOTENSION, CARDIAC ARREST, DYSPNOEA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Dalim Tissen in connection with ADENOSINE. Always verify the specific product and NDC with your pharmacist.